Symmetry Partners, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Symmetry Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 11, 2024	BUY	$143.31 - $247.0 $163,946 - $282,568	1,144 New	1,144 $278,000
Q4 2023 Jan 02, 2024	SELL	$151.41 - $196.57 $28,313 - $36,758	-187 Reduced 14.05%	1,144 $224,000
Q3 2022 Oct 03, 2022	BUY	$138.54 - $232.0 $184,396 - $308,792	1,331 New	1,331 $266,000
Q2 2022 Jul 11, 2022	SELL	$120.42 - $169.29 $160,279 - $225,324	-1,331 Closed	0 $0
Q2 2021 Jul 07, 2021	BUY	$128.63 - $176.89 $171,206 - $235,440	1,331 New	1,331 $226,000

647

109M

1.28M

1.22M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.9B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Symmetry Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Symmetry Partners, LLC with notifications on news.